Annual Report 2025

Compensation of the Board of Directors for 2025

The following table discloses the compensation paid to the members of the Board of Directors for financial year 2025 while performing services for medmix:

2025

thousands of CHF

Cash fees

Restricted share unit (RSU) plan1)

Social security contributions2)

Total

Rob ten Hoedt, Chairman

150

150

21

321

Barbara Angehrn

65

65

10

140

Daniel O. Flammer

65

65

10

140

David Metzger

65

65

10

140

Marco Musetti

73

73

11

157

Susanne Hundsbaek-Pedersen

65

65

10

140

Board of Directors

483

483

72

1’038

1)RSU awards granted in 2025. Grant price was CHF 9.5448 (three-week volume weighted average share price immediately prior to the Grant Date/AGM)

2)The amount includes mandatory social security contributions on the cash fees and estimated contributions on the RSU (based on their fair value at grant) paid by the company on behalf of the Board members.

The following table discloses the compensation paid to the members of the Board of Directors for financial year 2024 while performing services for medmix:

2024

thousands of CHF

Cash fees

Restricted share unit (RSU) plan3)

Social security contributions4)

Total

Rob ten Hoedt, Chairman

150

150

22

322

Barbara Angehrn

65

65

10

140

Daniel O. Flammer

65

65

10

140

David Metzger

65

65

10

140

Marco Musetti

73

73

12

158

René Willi 1)

26

6

3

35

Susanne Hundsbaek-Pedersen 2)

45

65

9

119

Board of Directors

489

489

77

1’055

1)Member of the Board of Directors until May 31, 2024.

2)Member of the Board of Directors from April 24, 2024.

3)RSU awards granted in 2024. Grant price was CHF 15.69 (three-week volume weighted average share price) and fair value was CHF 15.02.

4)The amount includes mandatory social security contributions on the cash fees and estimated contributions on the RSU (based on their fair value at grant) paid by the company on behalf of the Board members.

As of December 31, 2025 and 2024, respectively, there were no outstanding loans or credits granted to the members of the Board of Directors, former members of the Board of Directors or related parties. In 2025 and 2024, respectively, no compensation was granted to former members of the Board of Directors or related parties.

Reconciliation between the reported board compensation and the amount approved by the shareholders at AGM

At the AGM 2025, shareholders approved a maximum aggregate compensation amount of CHF 1'500'000 for the Board of Directors for the period of office from the 2025 AGM until the end of the 2026 AGM. The table below shows the reconciliation between the compensation that was/will be paid out for the periods of office and the maximum aggregate compensation amounts approved by the shareholders.

thousands of CHF

Compensation earned during financial year as reported (A)

Less compensation earned from Jan to AGM of financial year (B)

Plus compensation accrued from Jan to AGM of year following financial year (C)

Total compensation earned for the period from AGM to AGM of medmix (A-B+C)

Amount approved by shareholders at respective AGM

Ratio between compensation earned for the period from AGM to AGM versus amount approved by shareholders

2025 AGM - 2026 AGM

2025

January 01, 2025 to 2025 AGM medmix

January 01, 2026 to 2026 AGM medmix

2025 AGM to 2026 AGM

2025 AGM

2025 AGM

Board of Directors Total

1’038

149

139

1’028

1’500

68.5%

Compensation earned during financial year as reported (A)

Less compensation earned from Jan to AGM of financial year (B)

Plus compensation accrued from Jan to AGM of year following financial year (C)

Total compensation earned for the period from AGM to AGM of medmix (A-B+C)

Amount approved by shareholders at respective AGM

Ratio between compensation earned for the period from AGM to AGM versus amount approved by shareholders

2024 AGM - 2025 AGM

2024

January 01, 2024 to 2024 AGM medmix

January 01, 2025 to 2025 AGM medmix

2024 AGM to 2025 AGM

2024 AGM

2024 AGM

Board of Directors Total

1’055

169

149

1’035

1’500

69.0%